DeutschNewstral
Article
wsj.com on 2015-02-12 11:05
Eisai Expects Strong Sales From New Cancer Drug
Related news
- MEisai to pull weight-loss drug due to cancer concernsmarketwatch.com
- FBristol-Myers boosts profit outlook on strong cancer-drug salesft.com
- MMerck tops earnings expectations, thanks to strong cancer-drug salesmarketwatch.com
After US approval, Japan OKs Leqembi, its first Alzheimer’s drug, developed by Eisai and BiogenSeattle Times- ACinema owner expects strong salesadelaidenow.com.au
Japan's Eisai agrees with U.S.-based Merck on potential $5.76 billion cancer drugs dealThe Japan Times- Alzheimer’s drug made jointly by Japan’s Eisai wins accelerated U.S. approvalThe Japan Times
- Eisai and Biogen apply for approval of Alzheimer’s drug in JapanThe Japan Times
- Eisai sees potential of new Alzheimer’s drug but costs remain concernThe Japan Times
- Biogen and Eisai revive plans for Alzheimer’s drug aducanumab, but prospects still shakyThe Japan Times
- New Alzheimer’s drug from Biogen and Eisai is just the beginningThe Japan Times
AstraZeneca PLC: AstraZeneca raises forecasts after strong Covid and cancer drug salesFinancial Times- AstraZeneca PLC: AstraZeneca beats estimates with strong cancer and diabetes drug salesFinancial Times
- AStrong sales lift Sirtex profitsadelaidenow.com.au
FDA Approves Teva’s Cancer DrugHaaretz
On-line drug sales accountability?dailysunnews.com- BAstraZeneca Jumps on Strong Cancer Drug Databarrons.com
Apple expects iPhone, services, to lead strong holiday salesSan Jose Mercury News- MAvis stock rallies as company expects still-strong Q1 salesmarketwatch.com
Etsy Beats Record 2020 Q3, Expects Strong Fourth Quarter SalesForbes